Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows: Effect of nomlabofusp administration on ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...

PPS said "posters advocating for specific positions on political positions are not student centered." It's unclear if a ...

At Beijing's largest antiques market, Panjiayuan, among the Mao statues, posters and second-hand books are prominent signs ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented additional analyses of the efficacy and safety of sebetralstat from phase 2 and phase 3 double-blind, ...

PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

BEIJING - At Beijing's largest antiques market, Panjiayuan, among the Mao statues, posters and second-hand books are ...

using anchored simulated treatment comparison of data from RATIONALE-302 and comparator clinical studies (poster #1417P, Sept. 16). "TEVIMBRA has shown potential across multiple disease states ...

It's National Suicide Prevention Week, so Bisnow explored what construction leaders are doing to solve their industry's ...

Overall, the Company believes that the results to date from the TAMARACK study indicate antitumor activity associated with vobra duo in mCRPC as demonstrated by the protocol-specified primary endpoint ...